CHEK2, breast cancer, and the understanding of clinical utility

Clinical Genetics

Volumn 78, Issue 1, 2010, Pages 8-10

  Robson, M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; TAMOXIFEN; CHEK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

BREAST CANCER; CANCER RADIOTHERAPY; DNA DAMAGE; DNA REPAIR; EDITORIAL; GENE MUTATION; GENETIC SCREENING; HUMAN; MASTECTOMY; PRIORITY JOURNAL; BREAST NEOPLASMS; CLINICAL PRACTICE; FEMALE; GENETICS;

BREAST NEOPLASMS; CHECKPOINT KINASE 2; FEMALE; GENETIC TESTING; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PROTEIN-SERINE-THREONINE KINASES;

EID: 77954601802     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2010.01444.x     Document Type: Editorial

References (12)

1. Antoni L, Sodha N, Collins I. CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat Rev Cancer 2007, 7:925-936.
2. Stracker TH, Usui T, Petrini JH. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) 2009, 8:1047-1054.
3. Bell DW, Varley JM, Szydlo TE. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999, 286:2528-2531.
4. Weischer M, Bojesen SE, Ellervik C. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 2008, 26:542-548.
5. Offit K, Garber JE. Time to check CHEK2 in families with breast cancer? J Clin Oncol 2008, 26:519-520.
6. Teutsch SM, Bradley LA, Palomaki GE. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med 2009, 11:3-14.
7. Byrski T, Gronwald J, Huzarski T. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010, 28:375-379.
8. Fong PC, Boss DS, Yap TA. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
9. Metcalfe KA, Lubinski J, Ghadirian P. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008, 26:1093-1097.
10. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008, 122:2017-2022.
11. Mellemkjaer L, Dahl C, Olsen JH. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study. Br J Cancer 2008, 98:728-733.
12. Domchek SM, Gaudet MM, Stopfer JE. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat 2010, 119:409-414.